KRAS::ETNK1 Fusion Identified in MDS/MPN Overlap With Eosinophilia

Researchers have identified a rare KRAS::ETNK1 fusion in a patient with an MDS/MPN overlap syndrome, marking a potential first in medical literature. The study tracks the genetic evolution of the disease following a stem cell transplant.
Why it matters
Identifying specific genetic mutations in rare cancers is essential for developing targeted therapies and understanding disease progression.
A man with a myelodysplastic/myeloproliferative neoplasm (MDS/MPN) overlap syndrome and eosinophilia carried a previously unreported KRAS::ETNK1 fusion transcript that was no longer detectable after allogeneic hematopoietic stem cell transplantation (HSCT), when his disease returned as secondary acute myeloid leukemia, according to a case report published in eJHaem.1 The authors, from Hospices Civils de Lyon in France, believe it is the first MDS/MPN case reported with the fusion.
At relapse, a new deletion on chromosome 12p covering both genes accounted for the fusion’s loss, and the leukemia had shed its myeloproliferative features. The investigators read that as a possible sign of immune editing after transplant, though they acknowledged their data could not show immune recognition of the fusion itself.
ETNK1 Alterations in MDS/MPN Overlap Syndromes
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in